SCHEMBL10060466

SCHEMBL10060466

CC(C)S(=O)(=O)c1ccc(-c2ccc(S(=O)(=O)C(C)C)cc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 4/20 0.46
CA2 P00918 4/20 0.46
CA9 Q16790 4/20 0.46
SMN1; SMN2 Q16637 2/20 0.41
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
MMP2 P08253 4/20 0.41
MMP9 P14780 4/20 0.41
MMP1 P03956 3/20 0.41
MMP13 P45452 3/20 0.41
MMP8 P22894 1/20 0.41
MMP12 P39900 1/20 0.41
MMP14 P50281 1/20 0.41
MMP16 P51512 1/20 0.41
ADAMTS4 O75173 2/20 0.40
CA1 P00915 2/20 0.39
CA14 Q9ULX7 1/20 0.39
TP53 P04637 1/20 0.39
POLB P06746 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10060475 0.92 ALDH1A1 (0.40) CA12CA2CA9SMN1; SMN2MMP2
SCHEMBL14519925 0.91 CA12 (0.54) CA12CA2CA9MMP2MMP9
SCHEMBL10078900 0.91 PTGS2 (0.48)
SCHEMBL5049911 0.89 MMP2 (0.53) CA12CA2CA9HTTMMP2
SCHEMBL2657775 0.82 ALDH1A1 (0.36) CA12CA2CA9SMN1; SMN2MMP2
SCHEMBL14520771 0.82 ENPP2 (0.52)
SCHEMBL178444 0.82 GAA (0.56) CA12CA2CA9SMN1; SMN2LMNA
Biphenyl SCHEMBL11056125 0.81 CA12 (0.46) CA12CA2CA9SMN1; SMN2LMNA
SCHEMBL2642589 0.80 ALDH1A1 (0.36) CA12CA2CA9SMN1; SMN2MMP2
SCHEMBL2646286 0.80 CA1 (0.47) CA12CA2CA9MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8648094-B2 IAP BIR domain binding compounds PHARMASCIENCE, INC. (CA) 2014-02-11 US disclosed
US-20120195915-A1 IAP BIR domain binding compounds PHARMASCIENCE INC. (CA) 2012-08-02 US disclosed
US-8163792-B2 IAP BIR domain binding compounds PHARMASCIENCE INC. (CA) 2012-04-24 US disclosed
US-20090192140-A1 IAP BIR DOMAIN BINDING COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2009-07-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120195915-A1 IAP BIR domain binding compounds BIRC5, BIRC2, BIRC3 CA12 4362/4885CA2 4198/4885CA9 4182/4885
US-20090192140-A1 IAP BIR DOMAIN BINDING COMPOUNDS BIRC5, BIRC2, BIRC3 CA12 4362/4885CA2 4198/4885CA9 4182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.